Introduction {#s0001}
============

Translation of mRNAs is highly regulated to ensure the proper quantity, time and location of protein synthesis. The output of protein from each mRNA is determined in part by its abundance and the status of the translation apparatus. Information within the transcript also controls protein expression, including cis-acting regulatory elements, RNA structure, and codon content. Specific regulatory elements that regulate a transcript\'s fate are often located in 5´ or 3´ untranslated regions (UTRs). Many regulatory elements are recognized by trans-acting RNA-binding factors that determine whether the transcript is translated or instead silenced, stored, localized, stabilized or destroyed.

In this review, we explore mechanisms of mRNA regulation by RNA-binding proteins (RBPs), focusing on 3 now-classic RBPs, Pumilio (Pum), Nanos (Nos) and Brain Tumor (Brat). To date, \>1500 RBPs have been cataloged and the functions of most remain to be discovered.[@cit0001] The sheer number of RBPs signifies the importance of post-transcriptional control. Pum, Nos and Brat were originally identified in *Drosophila* decades ago and remain relevant because they exemplify key principles of post-transcriptional control and because they regulate crucial biological functions. Recently, important new insights into their molecular mechanisms illuminate our understanding of regulated RNA stability and the spatial and temporal control of protein expression.

Combinatorial control is emerging as a pervasive theme in post-transcriptional regulation, with mRNAs controlled by a dynamic constellation of RNA-binding factors. Pum, Nos and Brat represent an archetypal example where their combined action controls crucial biologic processes including development, stem cell proliferation, fertility and neurological functions. Genetics revealed overlapping functions, and they were shown to physically interact with each other on a target mRNA, leading to a compelling model some 15 y ago.[@cit0005] Yet the mechanism of combinatorial control was not well understood. Recent advances provide the detailed molecular basis of their collaboration. We now understand that Pum, Nos and Brat proteins each define a protein family with unique modes of RNA recognition. Certain transcripts can be targeted by all 3 RBPs, which bind cooperatively to synergistically repress protein expression. Here we introduce the unique features of Pum, Nos and Brat proteins, and integrate new biochemical, structural and functional data into an updated model of their combinatorial regulatory function. We then explore the implications of this model for regulation of mRNAs on a transcriptome-wide scale.

Pumilio {#s0001-0001}
-------

Pum is a founding member of the PUF (Pum and *fem-3* binding factor) family of eukaryotic RNA-binding proteins.[@cit0008] Pum was originally identified as a maternal effect gene necessary for embryonic development.[@cit0009] The name Pumilio is Latin for "dwarf," referring to the small embryos from the original *pum* mutant. Subsequently, Pum was shown to regulate diverse biologic processes including germline stem cell proliferation, fertility, neuronal morphology, motor neuron electrophysiology, and memory formation.[@cit0011]

Pum is a 1533 amino acid residue protein with a conserved Pum homology domain (Pum-HD) located in the C-terminal third ([Fig. 1A](#f0001){ref-type="fig"}). The Pum-HD, which defines the PUF family, is a sequence-specific RNA-binding domain of ∼40 kDa composed of repeated triple α helical units.[@cit0006] Pum has 8 repeats that form a crescent shaped molecule, and each repeat presents 3 amino acid residues that recognize a single RNA nucleotide.[@cit0018] Pum thereby binds an 8 nucleotide, single-stranded RNA sequence with the consensus 5´-UGUANAUA (where N = A, G, C or U), herein referred to as the Pum Response Element (PRE) ([Fig. 1B](#f0001){ref-type="fig"}).[@cit0019] X-ray crystal structures of the RNA-binding domains of PUF proteins bound to RNA ligands, including the high resolution structure of Pum bound to a PRE, clearly illustrate the modular RNA recognition, and recent reviews provide a comprehensive discussion of the determinants of PUF RNA-binding specificity ([Fig. 1C](#f0001){ref-type="fig"}).[@cit0019]

Pum binds and represses specific mRNAs that contain one or more PREs, resulting in reduced protein expression and accelerated mRNA degradation.[@cit0027] We now understand that Pum repression occurs through multiple mechanisms. The Pum-HD represses by targeting the poly(A) tail of target mRNAs. Normally, the poly(A) tail acts to promote translation and stability of an mRNA, mediated by poly(A) binding protein, PABP. We found that the Pum-HD associates with and antagonizes the translational activity of PABP, thereby contributing to repression.[@cit0028] The Pum-HD also directs repression by promoting removal of poly(A) from target mRNAs by recruiting the Pop2 deadenyase enzyme,[@cit0028] which is part of the Ccr4-Not complex (CNOT) that catalyzes deadenylation and causes translational repression.[@cit0033] Notably, poly(A)-dependent repression mechanisms are conserved functions of PUF proteins.[@cit0028]

Pum also elicits poly(A)-independent repression. In both cultured cells and embryos, Pum represses reporter mRNAs lacking a poly(A) tail, albeit with reduced efficiency.[@cit0028] Structure-function analysis revealed that the N-terminus of Pum, wholly outside of the Pum-HD, conferred poly(A)-independent repression activity.[@cit0027] The N terminus was largely a mystery as it is not homologous to other proteins or domains. However, genetic evidence indeed supports the importance of the Pum N terminus, as its inclusion in transgenes was necessary to fully rescue developmental defects of a *pum* mutant.\[20\] Dissection of the Pum N terminus revealed 3 autonomous repression domains capable of poly(A)-independent repression, potently inhibiting protein expression and stimulating mRNA decay when targeted to a reporter mRNA.[@cit0027] It remains to be determined how each Pum repression domain operates.

Nanos {#s0001-0002}
-----

Nos is a founding member of the eukaryotic Nos protein family, with orthologs found throughout multicellular eukaryotes. Nos was originally identified as a maternally provided determinant of posterior development.[@cit0010] The name *nanos* is Greek for "dwarf" and describes the morphology of original mutant embryos, which is identical to the *pum* phenotype.[@cit0038] In fact, Nos shares several biological roles with Pum including embryonic development, control of germline stem cell proliferation, neuronal morphology, and long-term memory formation.[@cit0011] These commonalities are indicative of collaborative control by Nos and Pum.

Nos protein is 401 amino acid residues in length with 2 unique C-terminal CCHC-type Zinc Finger (ZF) domains that define the Nanos family ([Fig. 1A](#f0001){ref-type="fig"}). The ZF domains were reported to mediate non-specific binding to RNA.[@cit0040] We recently found that Nos ZFs bind specifically to a Nanos Binding Site (NBS) in RNA, but only when that RNA includes a downstream PRE sequence that is bound by Pum (discussed further below) ([Fig. 1B](#f0001){ref-type="fig"}).[@cit0019] Crystal structures of the ZFs of Nos bound to RNA in conjunction with Pum provide evidence of specific nucleotide binding pockets formed by the tandem ZF domains ([Fig. 1C](#f0001){ref-type="fig"}).[@cit0019]

Like Pum, Nos is a repressor that reduces protein expression and stimulates decay of target mRNAs.[@cit0042] Recent research has revealed that Nos binds and recruits the CNOT complex to repress translation and elicit decay by promoting deadenylation and decapping of the 5´ 7-methyl guanosine cap structure.[@cit0044]

Brain Tumor {#s0001-0003}
-----------

Brat is an RBP with important roles in oogenesis, embryogenesis and the nervous system.[@cit0005] Brat was originally identified as a growth suppressor in the larval brain, its name derived from the mutant phenotype wherein neural cells aberrantly proliferate.[@cit0048] Brat has many documented functions including regulation of neuromuscular junction formation, neuronal differentiation, axon maintenance in mushroom bodies and control of motor neuron electrophysiology.[@cit0039] Brat has overlapping functions with Pum and Nos in the germline and embryo, as discussed below, and also has functions independent of Pum and Nos.[@cit0005]

Brat is a 1037 amino acid residue protein that belongs to the TRIM-NHL class of proteins, which are defined by an N-terminal TRIM (Tripartite Motif) and C-terminal NHL (NCL-1, HT2A, and Lin-41) domain ([Fig. 1A](#f0001){ref-type="fig"}).[@cit0054] The C-terminal NHL domain forms a 6-bladed β propeller structure that is crucial for function.[@cit0007] Initially, Brat was thought to function as an adaptor protein that mediated protein-protein interactions[@cit0005]; however, the NHL domain of Brat was recently shown to be an RNA-binding domain, specifically recognizing the Brat binding site (BBS) with consensus 5´-WYGUUD (where W = A or U; Y = U or C; D = G, A, or U) ([Fig. 1B](#f0001){ref-type="fig"} and [Fig. 1C](#f0001){ref-type="fig"}).[@cit0029] The TRIM region of Brat contains 2 B-box type ZFs, which are broadly found in DNA- and RNA-binding proteins, but it is unknown whether these domains contact RNA.

Like Pum and Nos, Brat represses translation from target mRNAs and accelerates their decay[@cit0005]; however, less is known about its mechanism. Evidence from embryos demonstrates that Brat causes turnover of numerous transcripts during the maternal-to-zygotic transition (MZT), a developmental stage in which maternally provided transcripts are degraded and zygotic genome transcription is initiated,[@cit0057] and this effect can be recapitulated in cultured cells with reporter mRNAs.[@cit0029] Brat appears to work in conjunction with the translational repressor protein, 4EHP (eIF4E homologous protein); the NHL domain was reported to interact with 4EHP, and 4EHP mutations reduced Brat-mediated repression.[@cit0053] Brat is also reported to associate with the CNOT deadenylase complex,[@cit0059] suggesting that it may promote deadenylation of mRNAs, although this supposition remains unproven.

Combinatorial control by Pumilio, Nanos and Brain Tumor: The hunchback mRNA paradigm {#s0001-0004}
------------------------------------------------------------------------------------

No case better exemplifies combinatorial control by Pum, Nos and Brat than collaborative regulation of *hunchback* mRNA, their first identified target in the early embryo.[@cit0060] Justified by its biological significance, intense focus on the mechanisms of *hunchback* regulation helped to establish key parameters of the Pum-Nos-Brat partnership.

During early embryogenesis in *Drosophila*, the zygotic genome is transcriptionally silent and development is directed by maternally supplied gene products.[@cit0057] Maternal mRNAs, including *hunchback*, must be precisely regulated for development to proceed. Hunchback is a transcription factor that controls body pattern formation, and its expression must be limited to the anterior portion of the syncytial embryo before the MZT.[@cit0064] Because *hunchback* mRNA is distributed throughout the embryo, its mRNA is translated only in the anterior while being repressed in the posterior to achieve proper spatial distribution of Hunchback protein.[@cit0061] Repression of *hunchback* is achieved by Pum, Nos and Brat, and mutations that inactivate them result in improper expression of the Hunchback protein in the posterior, subsequent loss of abdominal segments, and developmental failure.[@cit0005]

The spatial distribution of Hunchback protein is determined by an opposing concentration gradient of Nos protein.[@cit0038] *nos* mRNA is localized to the embryo\'s posterior where its localized translation, coupled to simultaneous repression of unlocalized *nos* mRNA in the bulk cytoplasm,[@cit0069] establishes a Nos protein gradient that is highest in the posterior, quickly diminishing toward the anterior. Pum and Brat proteins are distributed throughout the embryo, and although crucial for *hunchback* mRNA regulation, they do not provide the spatial cue.[@cit0005] In addition to controlling *hunchback* translation during early embryogenesis, the combinatorial action of Pum and Brat (and likely Nos) mediates degradation of maternally provided *hunchback* mRNA during the MZT.[@cit0029]

Early work mapped the features of *hunchback* mRNA necessary for Nos-mediated repression. Two separate Nanos Response Elements (NREs) were identified within the *hunchback* mRNA 3´UTR that are necessary and sufficient to confer Nos-mediated repression in embryos.[@cit0040] Each NRE contains 2 distinct, conserved elements termed Box A and Box B, which are required for complete regulation ([Fig. 1B](#f0001){ref-type="fig"}). These NREs are the nexus for combinatorial regulation of *hunchback* mRNA by Nos, Pum and Brat.

The Nanos Response Element is directly bound by Pumilio, Nanos and Brain Tumor {#s0001-0005}
------------------------------------------------------------------------------

A synthesis of early and recent discoveries firmly establishes direct binding and combinatorial regulation of *hunchback* mRNA by Nos, Pum and Brat. Pum was first shown to bind each NRE element of *hunchback*.[@cit0022] The Pum-NRE interaction was interrogated through mutational analysis and binding assays, defining a high affinity PRE within each NRE bound by a single Pum.[@cit0021] Structural, high throughput selection and sequencing, and transcriptome-wide analyses corroborated and defined the specificity of the Pum-PRE interaction.[@cit0018] We now understand that each *hunchback* NRE contains a single high affinity 8 nucleotide PRE, the 5´ half of which overlaps with each conserved Box B element ([Fig. 1B](#f0001){ref-type="fig"}).

Insight into the role of Nos in *hunchback* regulation emerged from structure-function analysis using Nos transgenes, which identified the ZFs and C terminus as being critical for *hunchback* regulation.[@cit0040] Purified, recombinant Nos was also reported to bind the NRE without apparent specificity, though we now understand that the NRE mutations tested were in fact outside the Nos binding site.[@cit0019] Key insights into the Nos-NRE interaction came from yeast 3-hybrid assays, which showed that Nos binds to the NRE in a Pum-dependent manner, and the resulting ternary complex could also be detected by *in vitro* pulldown assays.[@cit0075] Mutations that disrupt Nos, Pum or NRE function prevented formation of the ternary complex. Nos did not bind the NRE in the absence of Pum; however, when Pum was included, Nos could be crosslinked to the RNA. Nos did not stably bind Pum in the absence of NRE RNA. These results indicated that Pum provides sequence-specific RNA-binding, whereas Nos recognizes a combination of Pum and RNA. Importantly, nucleotides upstream of the PRE were shown to be important for incorporation of Nos into this ternary complex.[@cit0075]

We recently reported biochemical, structural and cell-based studies that show how Nos and Pum cooperatively bind NRE RNA.[@cit0019] Using RNA electrophoretic mobility shift assays (EMSA), we found that Nos tightly binds the Pum-NRE complex and increases the affinity of Pum for the NRE, correlating with its ability to enhance translational repression in cells in a dosage dependent manner. A critical revelation is that Pum does not merely recruit Nos for repression activity; Nos enhances the binding of Pum to *hunchback* RNA, bringing the combined repressive activities of Nos and Pum to bear on *hunchback* mRNA exclusively in the embryonic posterior where Nos concentration is highest.[@cit0019]

Our crystal structure of the Nos-Pum-NRE ternary complex illuminated the mechanism of Nos-Pum cooperativity.[@cit0019] Pum recognizes the PRE sequence in the recognizably modular fashion, while Nos embraces both Pum and RNA, effectively clamping them together ([Fig. 1C](#f0001){ref-type="fig"}). The Nos C terminus interacts with a loop region between the 7th and 8th repeats of the Pum-HD. Conformational changes in the loop of Pum are induced by the Nos interaction, which enables an α helix at the C terminus of the Pum-HD to unfold and contact the NRE. Mutational analysis affirmed the importance of observed interactions for complex formation *in vitro* and repression activity in cells.[@cit0019] The observed contacts also illustrate how mutants of Pum (mutations in the loop between repeat 7 and 8), Nos (mutations in the ZFs or C terminus) and Box B of the NRE result in loss of *hunchback* mRNA regulation in embryos.[@cit0020] Figure 1.Pum, Nos, and Brat are RNA-binding proteins that bind the *hunchback* mRNA. (A) Schematic diagrams of Pum, Nos, and Brat proteins with relevant domains labeled: Pum N-terminal Repression Domains (RD1, RD2, and RD3), and Pum Homology Domain (Pum-HD); Nos Effector Domain (NED), Zinc Fingers (Z), and C-terminal extension (C); Brat B-box Zinc Fingers 1 and 2 (B1 and B2), coiled coil (CC), and NCL^-^1, HT2A, and Lin-41 (NHL) domain. (B) Pum, Nos and Brat bind to the Nanos Response Element 2 (NRE2) RNA from the *hunchback* 3´UTR with color-coded binding sites for Brat, Nos, and Pum. Box A and B elements of the NRE are outlined by a black box. Direct interactions are indicated by solid lines whereas dashed lines indicate putative interactions. The loop between repeats 7 and 8 of Pum, which mediates protein-protein interaction with Nos, is shown in black. (C) Structural model of Brat (NHL domain), Nos (ZC regions), and Pum (Pum-HD) proteins with NRE RNA. The crystal structures of Brat in complex with a BBS (red, PDB ID 4ZLR) and Nos (blue)/Pum (yellow) in complex with NBS-PRE RNA (PDB ID 5KL1) are shown with the 4 nucleotide spacer RNA (gray) present in the native *hunchback* NRE2 RNA. Brat and Pum proteins are shown as ribbon diagrams. Nos is shown with a molecular surface superimposed. Residue G1330 of Pum is highlighted by a yellow sphere.

Our Nos-Pum-NRE structure revealed that the tandem ZFs of Nos bind 3 nucleotides immediately upstream of the PRE, defining the NBS ([Fig. 1B](#f0001){ref-type="fig"}).[@cit0019] By performing Nos-Pum selection of a randomized RNA library and high throughput sequencing (SEQRS), we showed that Nos confers specificity for A/U rich NBS sequences in the presence of Pum.[@cit0019] Nos-NBS specificity is verified in cells and embryos, where mutations of the NBS prevent Nos-mediated repression.[@cit0019] Together, these data support a model wherein Nos acts as a clamp that promotes the binding of Pum to the NRE, and together they recognize an extended NBS+PRE sequence encompassing the Box B region of the NRE ([Fig. 1C](#f0001){ref-type="fig"}). In turn, the ternary complex elicits robust repression of *hunchback* mRNA.

Brat was identified as a third protein recruited by the Nos-Pum-NRE ternary complex.[@cit0005] Using a yeast 4-hybrid strategy, the Brat NHL domain was found to bind the Pum-Nos-*hb* NRE complex. Yeast interaction and *in vitro* pulldown assays indicated that Nos and Pum were both needed to recruit Brat to the NRE. Yet no direct interaction of Brat with NRE, Nos or Pum individually could be detected by these means. A model was put forth wherein Pum and Nos bind the NRE and then recruit Brat through simultaneous protein-protein interactions with Nos and Pum to form a quaternary complex.[@cit0005] Genetic analysis showed that *brat* mutants disrupted *hunchback* mRNA regulation and abdominal segmentation in embryos, mirroring the effects of Nos, Pum or NRE mutants.[@cit0005]

New data on Brat\'s RNA-binding properties and its interaction with the NRE warrant a re-evaluation of the quaternary complex model. Three studies have now shown that Brat is an RNA-binding protein that directly contacts the Box A sequence in each *hunchback* NRE ([Fig. 1B](#f0001){ref-type="fig"}).[@cit0029] A crystal structure of the Brat NHL domain bound to RNA revealed an electropositive surface of the NHL domain that recognizes the 6 nucleotide, single-stranded RNA element, and mutation of observed Brat-RNA contacts (including R875A, F916A, and N933A) disrupted its RNA-binding and cellular repression activities.[@cit0055] Based on these data, it is now apparent that Brat does not require Pum and Nos to bind the NRE. Although Brat and Pum are able to bind to the NRE cooperatively,[@cit0055] it is unclear whether protein-protein interactions underlie this cooperative binding, since a Brat-Pum interaction could not be detected in the absence of NRE RNA.[@cit0055] One proposal is that cooperative Brat-NRE-Pum binding is mediated by changes in RNA secondary structure induced by protein-RNA contact.[@cit0056] More importantly, it remains uncertain whether the observed cooperative binding even impacts repression activity, since synergism between Brat and Pum has not yet been demonstrated.[@cit0055]

New insights from structure-function analyses also prompt reassessment of the effects of specific mutations on the quaternary complex, as summarized in [Table 1](#t0001){ref-type="table"}. For example, Pum mutants C1365R, T1366D, or N1368S were reported to disrupt Brat recruitment,[@cit0006] but the Nos-Pum-NRE structure shows that these residues are at the Nos-Pum interface, and thus are unlikely to interact with Brat in a quaternary complex.[@cit0019] Pum mutant G1330D, which is located in a loop between repeats 6 and 7 of the Pum-HD ([Fig. 1C](#f0001){ref-type="fig"}), does not affect RNA binding or cellular repression activities.[@cit0005] Moreover, G1330D does not contact Nos in the ternary complex structure, nor does it compromise Nos-Pum synergy ([Fig. 1C](#f0001){ref-type="fig"}).[@cit0019] Instead, G1330D was proposed to mediate Brat-Pum interaction,[@cit0005] but no assay has detected this putative protein-protein interaction and its effect on cooperative RNA binding by Pum and Brat has not been evaluated. Table 1.List of documented Pum, Nos, and Brat mutants which disrupt protein-protein and protein-RNA interactions, comparing the interpretations from the "Original Model" relative to the "New Model" based on recent studies, as cited in the table.ProteinMutationOriginal ModelNew ModelReferencePumG1130DBinding to Nos-Pum-NREUnknown[@cit0005]PumC1365RBlocked binding to Nos-Pum-NRELocated at the interface of Nos-Pum, predicted to disrupt binding to Nos[@cit0006; @cit0019]PumT1366DBlocked binding to Nos-Pum-NRELocated at the interface of Nos-Pum, predicted to disrupt binding to Nos[@cit0006; @cit0019]PumN1368SBlocked binding to Nos-Pum-NRELocated at the interface of Nos-Pum, predicted to disrupt binding to Nos[@cit0006; @cit0019]NosM378A or KBlocked binding of Brat to Nos-Pum-NRENecessary for Nos-Pum binding to NRE[@cit0005; @cit0019; @cit0027]Brat^fs1^G774DBlocked binding to Nos-Pum-NREEffect on NRE binding unknown. Reported to disrupt Brat binding to Mira.[@cit0005; @cit0050; @cit0056]Brat^fs3^H802LBlocked binding to Nos-Pum-NREReduced affinity for NRE, but does not directly contact RNA[@cit0005; @cit0055; @cit0056]BratY829ABlocked binding to Nos-Pum-NREReduced binding to NRE[@cit0007; @cit0055; @cit0056]BratR847ABlocked binding to Nos-Pum-NREReduced binding to NRE[@cit0007; @cit0055; @cit0056]BratR875ABlocked binding to Nos-Pum-NREBlocked binding to NRE[@cit0007; @cit0055; @cit0056]BratG860D Disrupt 4EHP interaction[@cit0053]BratK809A/E810A Disrupt 4EHP interaction[@cit0053]BratK882E Disrupt 4EHP interaction[@cit0053]

Nos was previously thought to be necessary for Brat recruitment to the NRE,[@cit0005] but direct binding of Brat to Box A obviates that conclusion. Moreover, the Nos mutant M378K (referred to as M379K in the original study) prevented Brat recruitment, but the Nos-Pum-NRE ternary complex revealed that this residue is at the interface of the Nos-Pum interaction and is necessary for Nos-Pum synergism.[@cit0019] The potential influence of Nos on Brat-NRE interaction remains to be re-evaluated considering this new information. What effect might Nos have on the Brat-NRE-Pum interaction? Since Nos enhances Pum affinity for the NRE, and Pum and Brat cooperatively bind the NRE, we speculate that Nos may enhance the Brat-NRE interaction acting through Pum. If true, this potential mutual cooperativity would be expected to contribute to spatiotemporal control of *hunchback* mRNA.

Several Brat mutations were originally attributed to disrupt protein-protein interactions with the ternary complex.[@cit0005] Instead, new information shows that these Brat mutations negatively affect its ability to bind RNA, including H802L (*brat^FS3^* allele)[@cit0005] and 3 residues located on the "top" electropositive interface (Y829A, R847A, R875A)([Table 1](#t0001){ref-type="table"}).[@cit0007] With the exception of H802, the crystal structure of a Brat-RNA complex shows that these mutated residues line the RNA-binding interface.[@cit0055]

Using current information, we illustrate a model of the quaternary complex on the *hunchback* NRE RNA ([Fig. 1C](#f0001){ref-type="fig"}). The model depicts interaction of the Brat NHL domain with its binding site overlapping Box A, the contacts of the Pum-HD bound to the PRE and the Nos-NBS interactions.[@cit0019] From a structural standpoint, it is not possible to dock the proteins consistent with the proposed Brat-Pum contacts. First, the Nos-Pum interface occludes the previously proposed interaction site for Brat on Pum.[@cit0007] As mentioned above, the previously modeled Brat-Pum interface is now known to be the RNA-binding interface. Moreover, the intervening 4 nucleotides between Box A and the NBS-PRE do not provide enough distance to permit interaction between the Brat NHL domain and Pum G1330 ([Fig. 1C](#f0001){ref-type="fig"}). Multiple features are missing from this model including the N termini of Brat, Nos and Pum, for which structural information is currently not available. Future biochemical and structural analyses are necessary to provide a more complete understanding of the quaternary complex architecture.

Multiple mechanisms of synergistic repression by Pumilio, Nanos and Brain tumor {#s0001-0006}
-------------------------------------------------------------------------------

Why are 3 repressors necessary to regulate *hunchback* mRNA? Redundancy is a possibility, but the fact that Pum, Nos and Brat are all required *in vivo* argues against that explanation. Instead, 4 principles have emerged. First, cooperative RNA binding contributes to the observed synergistic regulation through increased RNA affinity and specificity, as documented for Nos and Pum.[@cit0019] Whether cooperative RNA binding by Brat and Pum also contributes to synergism remains unknown. Second, each regulator is independently capable of repression, and therefore their collaborative regulation provides multiple repression mechanisms that inhibit translation and accelerate mRNA decay. Pum can repress PRE-containing mRNAs independent of Nos or Brat.[@cit0027] Brat can repress mRNAs bearing BBS motifs independent of Nos and Pum.[@cit0055] Nos also possesses its own repression activity, as demonstrated by artificial tethering Nos directly to mRNA[@cit0031]; however, in the natural context, it requires Pum.[@cit0019] Acting together, the combined activities of Brat, Nos and Pum offers increased magnitude of repression, as shown by synergistic repression by Nos and Pum,[@cit0019] though synergism between Brat and Pum has not been demonstrated.[@cit0055] The third principle is that the repressors each contact specific subunits of the same effector complex, as described for the CNOT complex below, resulting in enhanced recruitment to the target mRNA. A fourth principle is that collaboration imparts versatility in the means of controlling protein expression. For instance, repression of Hunchback protein synthesis is caused by translational inhibition and deadenylation early in embryogenesis followed by *hunchback* mRNA degradation during the MZT.[@cit0029]

Collaborative repression by Pum, Nos and Brat is mediated through multiple mechanisms, as shown in [Fig. 2](#f0002){ref-type="fig"}. Repression of translation by Pum, Nos and Brat is caused by inhibition of both 5´ cap and poly(A)-mediated translation ([Fig. 2A](#f0002){ref-type="fig"}). First, Pum antagonizes the translational activity of PABP; PABP interference has been demonstrated in cellular repression assays,[@cit0028] but the use of this poly(A)-mediated mechanism in the embryo must be verified. Second, Brat recruits 4EHP, which inhibits translation by displacing eIF4E from the 5´ cap structure.[@cit0053] Supporting this mechanism, the cap binding activity of 4EHP is required *in vivo*. However, it is important to note that mutation of 4EHP reduces, but does not eliminate, repression of Hunchback expression *in vivo,*[@cit0053] consistent with multiple repression mechanisms. Brat mutants (G860D, K809A/E810A, R837D, K882E) that prevent 4EHP recruitment were identified, and Brat R837D or K882E did not repress *hunchback* mRNA in embryos.[@cit0053] In cellular repression assays, however, the Brat R837D mutation had no effect, providing conflicting information about the importance of 4EHP recruitment for Brat-mediated repression in all contexts.[@cit0055] Third, Nos causes translational repression in cell-based assays via a Nos Effector Domain (NED) in the protein\'s N terminus.[@cit0044] The mechanism of this Nos-mediated translational repression is currently unknown, but might involve the action of CNOT complex and associated translational repressors 4E-T and Me31B (homolog of mammalian DDX6).[@cit0077] Figure 2.Multiple mechanisms of repression by Pum, Nos, and Brat. (A) Translational repression of target mRNAs can be mediated through recruitment of alternative cap-binding protein 4EHP by Brat, which is proposed to prevent binding of eIF4F translation initiation complex to the 5´ cap structure (7-methyl guanosine 5´-5´ triphosphate, m7Gppp). In addition, Pum antagonizes the translation activity of Poly(A) binding protein (PABP). (B) mRNA decay can be initiated through recruitment of the Ccr4-NOT (CNOT) complex, which catalyzes deadenylation and promotes decapping of the target mRNA. Pum recruits the Pop2 deadenylase to stimulate deadenylation, and Nos directly recruits Not1 and Not3 of the CNOT complex to stimulate deadenylation and decapping. Solid lines indicate documented interactions whereas dashed lines indicate putative interactions.

Pum, Nos and Brat also accelerate mRNA decay through multiple mechanisms, with collaborative recruitment of the CNOT complex emerging as a central theme.[@cit0027] Both Nos and Pum promote deadenylation by recruiting the CNOT complex,[@cit0028] The Pum-HD binds the Pop2 deadenylase subunit,[@cit0028] whereas the Nos NED contacts the CNOT1 and CNOT3 subunits.[@cit0044] Brat also associates with the CNOT complex,[@cit0059] but the contacts and its effect on deadenylation remain to be determined. When combined on NRE-containing mRNA, Brat, Nos and Pum may synergistically enhance deadenylase recruitment, resulting in accelerated deadenylation and subsequent mRNA decay.[@cit0033] To test this prediction, the contributions of the individual RBP-CNOT contacts on decay of *hunchback* mRNA should be evaluated in embryos. Nos also accelerates 5´ decapping ([Fig. 2](#f0002){ref-type="fig"}), and inactivation of the decapping enzyme Dcp2 blocked Nos-mediated mRNA decay, as did depletion of CNOT3.[@cit0044] It remains unclear whether Nos directly contacts the decapping enzyme. Alternatively, Dcp2 may be linked to Nos through the CNOT complex, which associates with decapping factors.[@cit0078]

Additional repression mechanisms appear to contribute to the repression of *hunchback* mRNA. For instance, we identified 3 repression domains (RDs) in the N terminus of Pum, each of which potently represses translation and promotes mRNA decay in cell-based assays.[@cit0027] Although the cofactors necessary for the activity of the Pum RDs must be identified, PABP and poly(A) are not essential for their activity.[@cit0028] Future research will focus on the mechanism of Pum RD repression and how they contribute to synergistic regulation to ensure proper spatial and temporal control of Hunchback protein expression.

Global impact of Pumilio, Nanos, and Brain Tumor on gene expression {#s0001-0007}
-------------------------------------------------------------------

With our new understanding of combinatorial control by Brat, Nos and Pum, it is now possible to survey their potential impact on the transcriptome (and thus proteome), both individually and collaboratively. Here we integrate experimental and transcriptome-wide predictions, revealing broad potential impact on gene expression. Target mRNAs fall into several categories ([Fig. 3](#f0003){ref-type="fig"}) including those individually targeted by Brat or Pum, jointly targeted by Brat and Pum, jointly targeted by Nos and Pum, and combinatorially controlled by all 3 RBPs. Figure 3.Classification of Pum, Nos, and Brat target mRNAs. Classification of target mRNAs regulated by Pum, Nos, and/or Brat, based on experimental evidence and bioinformatics analysis of *Drosophila* 3´UTRs using RNA-binding affinity, specificity, and cooperativity. Brat Binding Site (BBS), Pum Response Element (PRE), relaxed PRE (rPRE), and Nos Binding Site (NBS), described in the text, are indicated for each of 6 categories.

To begin, we integrated experimental evidence from several transcriptome-wide studies that used RNA-protein coimmunoprecipitation with microarray (i.e. RIP-Chip) to identify mRNAs bound by Pum and Brat. Unfortunately, no such data set exists for Nos. Gerber et al. identified mRNAs enriched by epitope-tagged Pum-HD purified from embryos or adult ovaries,[@cit0023] and Laver et al. performed RIP-Chip of endogenous Pum from early embryos.[@cit0029] Together, 1163 Pum-associated mRNAs were reported; of these, 679 have a consensus PRE. Laver et al. also identified mRNAs that copurified with endogenous Brat from early embryos, and Loedige et al. identified mRNAs enriched by epitope-tagged Brat purified from late-stage embryos.[@cit0029] When combined, 3601 mRNAs were associated with Brat, with 605 shared between data sets, and 3117 mRNAs contain a BBS. Together, this evidence indicates widespread targeting of mRNAs by Pum or Brat, a conclusion that is bolstered by the fact that Pum and Brat repress translation and promote decay of many mRNAs during embryogenesis.[@cit0029]

Comparison of the Pum- and Brat-bound mRNAs reveals an overlap of 484 mRNAs, indicating the potential coregulation of many mRNAs. Functional assays lend support for dual regulation of several mRNAs by Brat and Pum.[@cit0029] For example, the *dMyc* mRNA, which contains 6 PREs and 46 BBS motifs, is repressed by Pum and Brat in the differentiating cystoblast and in cellular repression assays, where Nos is absent.[@cit0056] However, since the majority of targets identified for each regulator did not overlap, Loedige et al and Laver et al (2015) concluded that Brat and Pum individually regulate most of their respective target mRNAs. It is noteworthy that these analyses focused on the early embryo and adult female germline and likely miss targets in different tissues and life stages, such as the nervous system, where Pum and Brat have documented roles.[@cit0013]

To survey the genome-wide regulatory potential of each RBP, we searched the 3´UTRs of all *Drosophila* mRNAs for potential binding sites. The results are summarized in Table S1, including number and location of each predicted binding site in annotated 3´UTRs isoforms (the numbers of sites cited in the text pertain to the longest isoform of unique genes). The PRE consensus 5´-UGUANAUA was derived from multiple approaches, including SEQRS, RNAcompete, and RIP-Chip, and validated by EMSA and structural analyses.[@cit0003] In total, 2477 mRNAs possess one or more PREs in their 3´UTR, including many potential targets with interesting biological implications. The mRNA encoding the antiproliferative protein, Tob, contains the highest number of PREs, with 12 found in its 3´UTR. The second and third highest number of PREs were in the *cpx* mRNA (11 PREs), encoding a protein involved in synaptic transmission, and eag mRNA (9 PREs), encoding a voltage gated potassium ion channel that controls neuronal excitability.

We used the consensus BBS, 5´-WYGUUD, derived from RIP-Chip and RNAcompete analyses and supported by EMSA and structural analyses,[@cit0029] and found that 9018 mRNAs contain at least one BBS. Note that we opted to include a C at nucleotide position 2 of the BBS search motif to be inclusive of the functional BBS of *hunchback* NRE1, which contributes to regulation[@cit0055] *in vivo,* though it is reported to be lower affinity relative to the BBS in NRE2.[@cit0055] Of all mRNAs containing BBS motifs, the *mei-P26* mRNA, which encodes another TRIM-NHL tumor suppressor involved in germline differentiation, contains the most at 76 potential sites. *Brat* mRNA contains the second highest number with 70 BBS motifs, supporting the potential for autoregulation, as suggested by Laver et al, 2015. Interestingly, the *smooth* mRNA, encoding a regulator of axon guidance, has 66 BBS sites.

A consensus binding site has not been found for Nos alone, despite our attempts.[@cit0019] Instead, Nos requires Pum for specific binding to RNA, and we identified a consensus NBS, encompassing 4 nucleotides upstream of the PRE, using SEQRS and corroborated by EMSA, Nos-Pum-RNA structures, and functional assays.[@cit0019] Nos binding to the NBS enhances binding of Pum to "perfect" consensus PREs, 5'-**DDWW**UGUANAUA (**NBS**+PRE), including those in the *hunchback* NREs. Some 1077 mRNAs have a 3´UTR with a NBS+PRE, with the *cpx* (8 motifs), *tob* (7 motifs), and *kruppel* (5 motifs) mRNAs containing the highest number of these motifs (Table S1).

Additionally, Nos enables Pum binding to "relaxed" PRE sites (rPRE), wherein nucleotides in position 5-8 of the PRE do not match the consensus (**NBS**+rPRE: 5'-**DDWW**UGUA).[@cit0019] This category includes Nos-Pum targets *bicoid* and *Cyclin B* and was validated by SEQRS, EMSA, a Nos-Pum-*Cyclin B* RNA crystal structure and cellular repression assays.[@cit0016] NBS+rPREs are present in 6225 mRNAs (Table S1). The *mei-P26* mRNA contains 47 such motifs in its 3´UTR, consistent with its CNOT-dependent repression by Nos and Pum in germline stem cells.[@cit0046] The *smooth* mRNA has the second most NBS+rPREs (41 motifs), suggesting a possible relationship of Pum and Nos to axon guidance. The longest *brat* mRNA isoform has 36 NBS+rPRE motifs (and no perfect PREs), which likely underlie the ability of Nos and Pum to repress its translation in germline stem cells.[@cit0080] We also analyzed the Pum-bound target mRNAs for the presence of these motifs and found significant enrichment: 56% have a PRE, 79% have NBS+rPRE and 28% have NBS+PRE (p values \< 0.002) relative to 19%, 52% and 8%, respectively, for all 3´UTRs. Based on these data, we predict that Nos expands the regulatory potential of Pum. In summary, our global target predictions suggest that regulation by Pum, Nos and Brat is pervasive.

We next asked how many transcripts may be combinatorially regulated by Brat and Pum and found that 2124 mRNAs possess both BBS and PRE motifs. In only 182 of these mRNAs, a BBS is located 1-13 nucleotides upstream of a PRE (BBSCPRE) (Table S1), the range of separation found in verified targets that are jointly regulated by Brat and Pum. We also assessed how many mRNAs possess binding sites for Brat, Nos and Pum and found that 1858 mRNAs possess at least one binding site for each protein within the 3´UTR (Table S1). The *paralytic (para)* mRNA, a known target of Brat, Nos and Pum belongs to this category.[@cit0039] *Para* encodes a sodium ion channel that functions in the larval motor neurons and its longest 3´UTR has one PRE, 26 NBS+rPRE sites and 19 BBS motifs. In fact, many of the predicted targets have the potential to be combinatorially regulated: nearly 81% of 3´UTRs with PRE or NBS+rPRE/PRE sites also possess BBS motifs, and reciprocally, 66% of 3´UTRs with BBS motifs also contain a PRE or NBS+rPRE/PRE. However, if we restrict the distance between the BBS and PRE motifs to \<13 nucleotides, as is the case in the *hunchback* NREs, only 24% of 3´UTRs with PRE or NBS+rPRE/PRE sites also possess an upstream BBS motif and only 19% of 3´UTRs with BBS motifs also contain a downstream PRE or NBS+rPRE/PRE. Together, these results indicate that collaborative regulation of many mRNAs is possible, but the extent depends on the importance of proximity of the RBP binding sites. Interestingly, only 63 mRNAs have a BBS located upstream (\< 13 nucleotides between BBS and PRE) of a NBS+PRE (a perfect NRE), and, most surprisingly, the only target with more than one such perfect NRE motif is *hunchback*, perhaps making it the most sensitive to Nos-Pum-Brat cooperative regulation (Table S1). The other genes in the perfect NRE category are enriched for gene ontologies of signal transduction (such as *tolloid, rhomboid* and *Ric*) and transcription (such as *knirps, sex combs reduced, clock,* and *drop*). Indeed, *knirps* mRNA is bound and repressed by Pum and Brat.[@cit0029] The *tolloid* mRNA has 3 BBS motifs in the context of a perfect NRE and encodes a metalloprotease that promotes Decapentaplegic (Dpp) signaling, which controls dorsal embryonic development and germline stem cell maintenance.[@cit0090] In addition, the *pum* mRNA contains a perfect NRE, supported by binding data, suggesting a means of feedback to regulate the regulator.[@cit0023] Overall, these results suggest that combinatorial regulation by Pum, Nos and Brat could impact many transcripts and biological processes, but functional analysis is essential to determine if cooperative RNA binding and synergistic repression are widespread.

These binding site predictions are informative and can stimulate future investigations, but have limitations that are important to acknowledge. Regulation will be affected by parameters that we cannot yet integrate, including the level, timing, and cell type expression of each RBP *in vivo*. Nos is a prime example. Nos is predominantly expressed in the adult ovary and early embryo,[@cit0093] though it also has documented roles in neurons.[@cit0013] Regulation of *Cyclin B* mRNA provides an example of cell type specific regulation.[@cit0031] Nos and Pum repress *Cyclin B* in primordial germ cells, which have a high concentration of Nos. The *Cyclin B* 3´UTR has no perfect PRE, but instead it possesses 5 NBS+rPRE motifs that confer regulation. *Cyclin B* also has 7 BBS motifs, but since Brat is absent in primordial germ cells, they are irrelevant for regulation in this cell type. *Mei-P26* mRNA is another example of cell-type specific regulation.[@cit0046] As noted above, its 3´UTR contains both perfect PREs and many NBS+rPREs, and it is repressed by Pum and Nos in germline stem cells. Despite its many BBS elements, *mei-P26* mRNA is not likely affected by Brat in germline stem cells, as *brat* mRNA itself is repressed in this cell type by Nos and Pum via multiple NBS+rPREs.[@cit0080] The expression pattern of the predicted targets will also determine whether they are regulated by Brat, Pum, and/or Nos, dictated by coincidence of target and regulator expression. In the example of *hunchback*, its mRNA is most highly expressed in early embryo and adult female ovary, coincident with high expression of Pum, Nos and Brat.[@cit0065]

The effect of the number, affinity, location, and spacing of each binding site is also not fully known. For our survey, we required that at least one binding site is present in the putative target. Indeed, for Nos and Pum, reporter assays indicate that one PRE or NBS+rPRE is sufficient to confer repression, and increased number and affinity of binding sites correlates with stronger repression.[@cit0019] For Brat, one binding motif can by recognized by the protein, but 2 BBS motifs in the same RNA were bound more tightly.[@cit0055] Moreover, in cellular repression assays, multiple BBS motifs conferred regulation by Brat, with 2 motifs being the minimum tested.[@cit0029] The relative orientation of the binding sites is also likely relevant. For Nos-Pum targets, the NBS must be directly upstream of the PRE.[@cit0019] For Brat-Pum targets, we allowed up to 13 nucleotides of separation between BBS and PRE, a parameter that is consistent with validated targets. The impact of the proximity of the BBS to an NBS or PRE is not known, although it is likely to affect collaboration. Based on cellular repression assays with reporter mRNAs, other spacing and arrangements of BBS and PRE motifs may be permissible for Brat or Pum-mediated repression,[@cit0056] but no data are available regarding cooperative RNA binding or synergistic repression.

RNA structure is likely to influence accessibility of the predicted binding sites, but how this parameter affects binding and regulation by Pum, Nos and Brat remains uncertain. Since each RBP binds a single-stranded RNA motif, structure may occlude or reduce binding affinity; however, evidence indicates that mammalian Pum proteins can disrupt double-stranded RNA to gain access to a PRE.[@cit0095] RNA binding by the Brat NHL domain was reduced when the BBS motif was within a stem loop of an RNA ligand that also contained a PRE, and addition of Pum strengthened binding, perhaps promoted by Pum\'s ability to disrupt RNA structure.[@cit0056] The ability of Nos and Pum to bind structured RNA cooperatively remains untested. Because of these remaining questions and lack of information on the effect of RNA structure on regulation *in vivo*, and the difficulties of accurately predicting RNA structure, we did not incorporate RNA structure predictions into our analysis at this time. Future research should address the relationship of RNA structure to binding and regulation of RNAs by Nos, Pum and Brat.

Alternative 3´ end processing of mRNAs could impact regulation by Brat, Nos and Pum in cases where their binding sites are altered. The *hid* mRNA, which is regulated by Nos and Pum in neurons,[@cit0094] is an example where 2 mRNA isoforms are produced by alternative 3´ end processing (Table S1): the *hid*-RA mRNA has a long 3´UTR with multiple NBS+PREs that is regulated by Nos-Pum, whereas these sites are eliminated in the shorter *hid*-RB version. Alternative processing of *para* mRNA produces 3 3´UTR isoforms: the longest has one perfect PRE, 26 NBS+rPRE motifs and 19 BBS motifs; the medium length isoform has multiple NBS+rPREs but no PRE; and the short isoform lacks these sites altogether. Intriguingly, regulation of *para* depends on Brat in certain neuronal subtypes but not others, perhaps the result of alternative processing of the 3´UTR or on differential expression of Brat.[@cit0039] In the case of *hunchback* mRNA, alternative 3´ end processing is developmentally regulated to produce 2 mRNA isoforms: a long 3´UTR present on the zygotically-expressed *hunchback*-RA mRNA and a short 3´UTR on the maternally-provided *hunchback*-RB isoform in early embryos. Importantly, each isoform contains both NRE elements.

Conclusion {#s0001-0008}
----------

With the revelation of many uncharacterized RBPs,[@cit0001] future studies are necessary to analyze their individual regulatory activities, RNA-binding specificities and target mRNAs. However, as exemplified by Pum, Nos and Brat, to succeed in understanding post-transcriptional regulatory networks, it is imperative to address combinatorial control. Control by the many more uncharacterized RBPs will likely involve cooperative RNA binding, altered specificity, and the interplay of multiple regulatory mechanisms that contribute to synergistic regulation or even bifunctional switches.[@cit0035] We have learned a great deal about the functions of Pum, Nos and Brat mediated regulation, but important challenges remain, including identification of combinatorially regulated mRNAs on a global scale, comprehensive dissection of the protein interaction network between the trio of RBPs and their corepressors, and interrogation of the multiple repression mechanisms *in vivo*. Future work should also extend the paradigms of *Drosophila* Pum, Nos and Brat to investigate the targets, RNA and protein interactions, and regulatory mechanisms of their mammalian homologs. Ultimately these efforts should uncover more of the underlying code of combinatorial regulation by RBPs.
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